Allied Biotech Corporation
Allied Biotech Corporation manufactures and sells carotenoids worldwide. Its products include Beta-Carotene that offers yellow to reddish orange shades to appeal color in various applications; Beta-Apo-8'-Carotenal, which is used as a food colorant, and provides a range of orange to red shades; and Lycopene, which offers a range of red shades as a nutrient for food, dietary supplements, and pharm… Read more
Allied Biotech Corporation (1780) - Total Liabilities
Latest total liabilities as of September 2025: NT$1.11 Billion TWD
Based on the latest financial reports, Allied Biotech Corporation (1780) has total liabilities worth NT$1.11 Billion TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Allied Biotech Corporation - Total Liabilities Trend (2019–2024)
This chart illustrates how Allied Biotech Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Allied Biotech Corporation Competitors by Total Liabilities
The table below lists competitors of Allied Biotech Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Warehouse Group Ltd
PINK:WHGPF
|
USA | $1.29 Billion |
|
GDB Holdings Bhd
KLSE:0198
|
Malaysia | RM212.23 Million |
|
Groupe LDLC SA
PA:ALLDL
|
France | €164.90 Million |
|
Micro Silicon Electronics Co., Ltd.
TW:8162
|
Taiwan | NT$1.09 Billion |
|
Best SA
WAR:BST
|
Poland | zł1.42 Billion |
|
Atari SA
PINK:PONGF
|
USA | $92.30 Million |
|
JNK Heaters Co. Ltd
KQ:126880
|
Korea | ₩102.64 Billion |
|
Super Energy Corporation Public Company Limited
BK:SUPER
|
Thailand | ฿50.73 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Allied Biotech Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Allied Biotech Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Allied Biotech Corporation (2019–2024)
The table below shows the annual total liabilities of Allied Biotech Corporation from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$1.06 Billion | +16.61% |
| 2023-12-31 | NT$910.12 Million | -8.93% |
| 2022-12-31 | NT$999.40 Million | -26.51% |
| 2021-12-31 | NT$1.36 Billion | +21.93% |
| 2020-12-31 | NT$1.12 Billion | +40.98% |
| 2019-12-31 | NT$791.06 Million | -- |